Black patients have higher rates of death after PCI

July 06, 2020

Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major adverse outcomes, including death, compared to white patients, according to a study published today in JACC: Cardiovascular Interventions. The study underscores the high rates of cardiovascular disease and risk factors in minorities and continued need for further research on race-based outcomes after cardiovascular procedures, including PCI, to understand and alleviate these differences.

It has been several decades since racial differences in cardiovascular outcomes were first reported. Blacks consistently have higher rates of cardiovascular risk factors and adverse outcomes compared with non-Hispanic whites, and both Blacks and Hispanics have been associated with increased risk of cardiovascular diseases.

"The variables that may contribute to the greater cardiovascular risks in minorities are multifactorial," said Gregg W. Stone, MD, senior author of the study and professor of cardiology at the Icahn School of Medicine at Mount Sinai in New York. "The variables include risk factors (e.g., greater hypertension, smoking and diabetes, and differences in body mass index), differences in cardiac structure (e.g., coronary artery size and left ventricular mass) and socioeconomic considerations (e.g., reduced access to care and/or insurance coverage, lack of preventative care, disease awareness and education, delayed presentation when ill, and in some studies varying provision of care)."

While previous studies have suggested that short- and long-term outcomes after PCI vary by race and cannot be fully explained by different baseline risk factors and treatment characteristics, other studies have failed to show a significant association. Furthermore, since current raced-based PCI outcomes have been acquired from registries and single-center studies lacking central monitoring and event adjudication, the authors of this study sought to assess the presence of racial disparities in clinical characteristics and outcomes from a large patient-level pooled database.

Researchers in this study used data from the Cardiovascular Research Foundation to analyze 10 prospective, randomized controlled trials with a combined total of 22,638 patients classified by race who underwent PCI. There were 20,585 (90.9%) white patients (reference group), 918 (4.1%) Black patients, 404 (1.8%) Asian patients, and 473 (2.1%) Hispanic patients. Other races were excluded from the analysis due to small sample sizes. Baseline characteristics such as body mass index (BMI) and PCI outcomes at 30 days, one-year, and five-years were assessed. Principal outcomes of interest were all-cause death, myocardial infarction (MI), and major adverse cardiac events (MACE), defined as the composite of cardiac death, MI or ischemia-driven target lesion revascularization.

Study findings showed in the five-year follow up after PCI, the MACE rates were 23.9% in Black patients compared with 18.8% in white patients, 21.5% in Hispanic patients and 11.2% in Asian patients. Multivariable analysis demonstrated an independent association between Black patients and five-year risk of MACE following PCI. Black patients also had higher rates of death in both the one- and five-year follow-ups after PCI compared to any other group. Results from the analysis showed that while enrolled in PCI, both Black and Hispanic patients had greater cardiovascular risk factors including diabetes, hypertension and hyperlipidemia than white and Asian patients.

"I am inherently optimistic, and I am hopeful that the increased societal attention to racial disparities prompted by recent social injustices will translate to improve health care and outcomes for minorities," Stone said. "But it won't just happen without active concerted efforts to promote change and opportunity, a task for government, regulators, payors, hospital administrators, physicians and all health care providers."

This study has several limitations, including Black and Hispanic patients were underrepresented in the trials so there is a potential for some selection bias; socioeconomic factors were not captured, which may influence differences in the risk of adverse outcomes after PCI; and the term "Hispanic" was designated as a race and not ethnicity, thereby potentially limiting the differences in outcomes between Hispanics and other races. Because this study included racial disparities in the three largest minority groups, further studies are required to address other minority groups and ethnicities/subgroups.

"Achieving representative proportions of minorities in clinical trials is essential but has proven challenging," Stone said. "We must ensure that adequate numbers of hospitals and providers that are serving these patients participate in multicenter trials, and trust has to be developed so that minority populations have confidence to enroll in studies. Language can be a barrier, requiring translation services and extra time and effort. Involvement of the families and primary care physicians who have an established relationship with patients in clinical trial discussions is useful....Finally, enrollment of non-Hispanic whites can be capped at a certain proportion of the total to ensure adequate enrollment of other racial and ethnic groups."

In an accompanying editorial comment, Eric D. Peterson, MD, MPH, professor of medicine in the Division of Cardiology at Duke University School of Medicine, said the study findings serve as a reminder of how large the racial gaps in cardiovascular disease treatments and outcomes are and continue to be.

"Solving racial health disparities is a crucial and pressing priority for all in health care," Peterson said. "We must all commit to reversing racial health disparities for tomorrow's generation. Talking is no longer enough; it is our responsibility to finally deliver effective solutions."
-end-
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit
The Journal of the American College of Cardiology ranks among the top cardiovascular journals in the world for its scientific impact. JACC is the flagship for a family of journals--JACC: Cardiovascular Interventions, JACC: Cardiovascular Imaging, JACC: Heart Failure, JACC: Clinical Electrophysiology, JACC: Basic to Translational Science, JACC: Case Reports and JACC: CardioOncology--that prides themselves in publishing the top peer-reviewed research on all aspects of cardiovascular disease. Learn more at

American College of Cardiology

Related Cardiovascular Disease Articles from Brightsurf:

Changes by income level in cardiovascular disease in US
Researchers examined changes in how common cardiovascular disease was in the highest-income earners compared with the rest of the population in the United States between 1999 and 2016.

Fighting cardiovascular disease with acne drug
Researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg and Stanford University have found the cause of dilated cardiomyopathy - a leading cause of heart failure - and identified a potential treatment for it: a drug already used to treat acne.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Dilemma of COVID-19, aging and cardiovascular disease
Whether individuals should continue to take angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the context of coronavirus disease 2019 (COVID-19) is discussed in this article.

Air pollution linked to dementia and cardiovascular disease
People continuously exposed to air pollution are at increased risk of dementia, especially if they also suffer from cardiovascular diseases, according to a study at Karolinska Institutet in Sweden published in the journal JAMA Neurology.

New insights into the effect of aging on cardiovascular disease
Aging adults are more likely to have - and die from - cardiovascular disease than their younger counterparts.

Premature death from cardiovascular disease
National data were used to examine changes from 2000 to 2015 in premature death (ages 25 to 64) from cardiovascular disease in the United States.

Ultrasound: The potential power for cardiovascular disease therapy
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Despite the ACA, millions of Americans with cardiovascular disease still can't get care
Cardiovascular disease (CVD) is the leading cause of death for Americans, yet millions with CVD or cardiovascular risk factors (CVRF) still can't access the care they need, even years after the implementation of the Affordable Care Act (ACA).

Excess weight and body fat cause cardiovascular disease
In the first Mendelian randomization study to look at this, researchers have found evidence that excess weight and body fat cause a range of heart and blood vessel diseases (rather than just being associated with it).

Read More: Cardiovascular Disease News and Cardiovascular Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.